Multivariate Analysis of Risk of Treatment Failure in Childhood B-Precursor ALL Patients With Informative Cytogenetic and Immunophenotyping Studies (N = 822)
| Adverse Variable . | P . | Estimated Risk Ratio . |
|---|---|---|
| . | . | (95% confidence limits) . |
| NCI poor-risk group | <.001 | 2.1 (1.5-2.9) |
| Not both +4 and +10 | .002 | 2.3 (1.4-4.0) |
| Brighter than 1st-quartile CD20 | .006 | 1.6 (1.1-2.2) |
| Brightest-quartile CD45 | .008 | 1.6 (1.1-2.2) |
| t(1; 19), t(4; 11), or t(9; 22) | .04 | 1.5 (1.0-2.3) |
| Adverse Variable . | P . | Estimated Risk Ratio . |
|---|---|---|
| . | . | (95% confidence limits) . |
| NCI poor-risk group | <.001 | 2.1 (1.5-2.9) |
| Not both +4 and +10 | .002 | 2.3 (1.4-4.0) |
| Brighter than 1st-quartile CD20 | .006 | 1.6 (1.1-2.2) |
| Brightest-quartile CD45 | .008 | 1.6 (1.1-2.2) |
| t(1; 19), t(4; 11), or t(9; 22) | .04 | 1.5 (1.0-2.3) |